AG2R LA Mondiale Gestion D Actifs Invests $1.45 Million in Biogen Inc. $BIIB

AG2R LA Mondiale Gestion D Actifs purchased a new position in Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, Holdings Channel reports. The firm purchased 8,264 shares of the biotechnology company’s stock, valued at approximately $1,454,000.

Several other hedge funds have also recently modified their holdings of BIIB. Convergence Investment Partners LLC purchased a new stake in Biogen during the third quarter valued at $1,342,000. Caprock Group LLC purchased a new stake in Biogen during the third quarter valued at $742,000. Leuthold Group LLC purchased a new stake in Biogen during the third quarter valued at $3,294,000. Generali Investments Management Co LLC increased its position in Biogen by 408.2% during the third quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock valued at $1,397,000 after acquiring an additional 8,008 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Biogen by 9.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 67,010 shares of the biotechnology company’s stock valued at $9,387,000 after acquiring an additional 5,987 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on BIIB shares. Oppenheimer upped their price objective on Biogen from $250.00 to $275.00 and gave the company an “outperform” rating in a research report on Wednesday, April 1st. The Goldman Sachs Group upped their price objective on Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Barclays started coverage on Biogen in a research report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 price objective for the company. Piper Sandler upgraded Biogen from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $177.00 to $214.00 in a research report on Tuesday, April 14th. Finally, Wells Fargo & Company boosted their price target on Biogen from $190.00 to $200.00 and gave the company an “equal weight” rating in a report on Sunday, February 8th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and a consensus price target of $214.23.

Biogen Stock Performance

NASDAQ:BIIB opened at $199.36 on Wednesday. The stock has a 50-day simple moving average of $184.68 and a two-hundred day simple moving average of $178.56. Biogen Inc. has a 52-week low of $119.18 and a 52-week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The firm has a market capitalization of $29.43 billion, a PE ratio of 21.39, a P/E/G ratio of 1.73 and a beta of 0.19.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the company posted $3.02 earnings per share. Biogen’s revenue for the quarter was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts forecast that Biogen Inc. will post 14.31 EPS for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.